Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Samama

Showing results (411-420 of 677) with videos related to

Pageof 68
Sort By:
Thrombosis and Haemostasis|May 6, 2011
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinuxM Wolzt, M M Samama, S Kapiotis, et al.
Acta Haematologica|January 1, 1973
[The effect of saturated and non-saturated fatty acids on the filtration pressure of platelet-rich plasma. Correlation with platelet aggregation]J F Stoltz, R J Prost-Dvojakovic, F Streiff, et al.
Annales De Medecine Interne|January 1, 1988
[Acquired factor VII inhibitor: treatment using high-dose immunoglobulins, corticotherapy and plasma exchange]A Delmer, G Andreu, M H Horellou, et al.
Journal Des Maladies Vasculaires|January 1, 1987
[Platelet aggregation tests in 26 cases of heparin-induced thrombopenia. Methodological, diagnostic problems and therapeutic aspects]C Lecrubier, T Lecompte, F Potevin, et al.
Journal of Thrombosis and Haemostasis : JTH|March 6, 2004
Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activityF Depasse, G T Gerotziafas, J Busson, et al.
International Angiology : a Journal of the International Union of Angiology|May 22, 2004
Potential use of D-dimer measurement in patients treated with oral anticoagulant for a venous thromboembolic episodeE Ombandza-Moussa, M M Samama, M H Horellou, et al.
Thrombosis Research. Supplement|January 1, 1988
Defective thrombolysis due to collagen incorporation in fibrin clotsM Mirshahi, J Soria, H Lu, et al.
Blood|August 1, 1988
Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosisG Nguyen, M H Horellou, E K Kruithof, et al.
Thrombosis and Haemostasis|July 31, 1998
Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparinP Toulon, B Boutière, M H Horellou, et al.
Journal of Thrombosis and Haemostasis : JTH|June 28, 2005
A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistanceL Bodin, M H Horellou, C Flaujac, et al.
Pageof 68

Showing results (411-420 of 677) with videos related to

Sort By:
Pageof 68
Thrombosis and Haemostasis|May 6, 2011
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinuxM Wolzt, M M Samama, S Kapiotis, et al.
Acta Haematologica|January 1, 1973
[The effect of saturated and non-saturated fatty acids on the filtration pressure of platelet-rich plasma. Correlation with platelet aggregation]J F Stoltz, R J Prost-Dvojakovic, F Streiff, et al.
Annales De Medecine Interne|January 1, 1988
[Acquired factor VII inhibitor: treatment using high-dose immunoglobulins, corticotherapy and plasma exchange]A Delmer, G Andreu, M H Horellou, et al.
Journal Des Maladies Vasculaires|January 1, 1987
[Platelet aggregation tests in 26 cases of heparin-induced thrombopenia. Methodological, diagnostic problems and therapeutic aspects]C Lecrubier, T Lecompte, F Potevin, et al.
Journal of Thrombosis and Haemostasis : JTH|March 6, 2004
Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activityF Depasse, G T Gerotziafas, J Busson, et al.
International Angiology : a Journal of the International Union of Angiology|May 22, 2004
Potential use of D-dimer measurement in patients treated with oral anticoagulant for a venous thromboembolic episodeE Ombandza-Moussa, M M Samama, M H Horellou, et al.
Thrombosis Research. Supplement|January 1, 1988
Defective thrombolysis due to collagen incorporation in fibrin clotsM Mirshahi, J Soria, H Lu, et al.
Blood|August 1, 1988
Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosisG Nguyen, M H Horellou, E K Kruithof, et al.
Thrombosis and Haemostasis|July 31, 1998
Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparinP Toulon, B Boutière, M H Horellou, et al.
Journal of Thrombosis and Haemostasis : JTH|June 28, 2005
A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistanceL Bodin, M H Horellou, C Flaujac, et al.
Pageof 68